基于PET影像组学指标预测局部晚期胰腺癌放化疗后无远处复发生存的训练与验证
PURPOSE: To assess the value of 18F-Fluorodeoxyglucose (18F-FDG) PET Radiomic Features (RF) in predicting Distant Relapse Free Survival (DRFS) in patients with Locally AdvancedPancreaticCancer (LAPC) treated with radio-chemotherapy.…
要点
- 由COMshift和P10两个一阶PET影像组学特征构成的指标可预测LAPC放化疗后DRFS。
- 训练组风险比2.72(95%CI 1.54-4.80,p=0.0005),验证组HR 2.53(95%CI 0.96-6.65,p=0.03)。
- 按四分位数分层,该指标可区分患者DRFS(p=0.0024,log-rank检验)。
核心结论
- 仅含两个稳健PET影像组学特征的指标可预测局部晚期胰腺癌患者放化疗后的无远处复发生存,有望用于治疗个体化。
主要发现
- 最终Cox模型纳入两个一阶影像组学特征:质心偏移(COMshift)和第10强度百分位数(P10)(p=0.0005,HR=2.72,95%CI=1.54-4.80),COMshift较低和P10较高的患者预后更差。
- 按四分位数分层(低于最低四分位 vs 高于最高四分位 vs 其余),该指标可对患者DRFS进行分层(p=0.0024,log-rank检验)。
- 验证队列中性能得到确认(p=0.03,HR=2.53,95%CI=0.96-6.65)。
- 加入临床因素未显著改善模型性能。
临床怎么用
- 可利用放疗前18F-FDG PET提取的COMshift和P10构建影像组学指标,辅助预测局部晚期胰腺癌放化疗后的远处复发风险。
- 该指标目前基于单中心数据,计划进行多机构独立验证后方可用于临床决策。
局限性
- 研究为单中心回顾性分析,验证队列样本量较小(60例),验证组HR的95%CI上限超过1。
- 原文指出已计划开展多机构独立验证,当前结果尚待外部验证确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the value of 18F-Fluorodeoxyglucose (18F-FDG) PET Radiomic Features (RF) in predicting Distant Relapse Free Survival (DRFS) in patients with Locally AdvancedPancreaticCancer (LAPC) treated with radio-chemotherapy. MATERIALS & METHODS: One-hundred-ninety-eight RFs were extracted using IBSI (Image Biomarker Standardization Initiative) consistent software from pre-radiotherapy images of 176 LAPC patients treated with moderate hypo-fractionation (44.25 Gy, 2.95 Gy/fr). Tumors were segmented by applying a previously validated semi-automatic method. One-hundred-twenty-six RFs were excluded due to poor reproducibility and/or repeatability and/or inter-scanner variability. The original cohort was randomly split into a training (n = 116) and a validation (n = 60) group. Multi-variable Cox regression was applied to the training group, including only independent RFs in the model. The resulting radiomic index was tested in the validation cohort. The impact of selected clinical variables was also investigated. RESULTS: The resulting Cox model included two first order RFs: Center of Mass Shift (COMshift) and 10th Intensity percentile (P10) (p = 0.0005, HR = 2.72, 95%CI = 1.54-4.80), showing worse outcomes for patients with lower COMshift and higher P10. Once stratified by quartile values (<lowest quartile vs >highest quartile vs the remaining), the index properly stratified patients according to their DRFS (p = 0.0024, log-rank test). Performances were confirmed in the validation cohort (p = 0.03, HR = 2.53, 95%CI = 0.96-6.65). The addition of clinical factors did not significantly improve the models' performance. CONCLUSIONS: A radiomic-based index including only two robust PET-RFs predicted DRFS of LAPC patients after radio-chemotherapy. The current results could find relevant applications in the treatment personalization of LAPC. A multi-institution independent validation has been planned.
引用
- Mori M, Passoni P, Incerti E, et al. Training and validation of a robust PET radiomic-based index to predict distant-relapse-free-survival after radio-chemotherapy for locally advanced pancreatic cancer. Radiother Oncol. 2020. PMID: 32681930. doi:10.1016/j.radonc.2020.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。